1. History of Hepatitis E {#sec1}
=========================

After the development of serological tests for the detection of hepatitis A and hepatitis B viruses in the 1980s, a large waterborne outbreak which occurred in 1955-1956 in New Delhi, India, was investigated and classified as enteric non-A, non-B hepatitis \[[@B1]\]. Same epidemiological investigation was performed in Kashimir, India, during a non-A, non-B hepatitis outbreak in 1978-1979 \[[@B2]\]. To both outbreaks, the laboratorial tests confirmed that hepatitis E virus (HEV) was the etiology agent \[[@B3], [@B4]\]. It was the first time that HEV was identified and associated with waterborne epidemics \[[@B3], [@B4]\].

Years later, in 1983, HEV was first identified by electron microscopy when they replicated the infection with a pool of human feces in one volunteer who had previously contacted with hepatitis A virus. It was also the first time to detect genotype 1 \[[@B4], [@B5]\].

Other cases occurred in Costa Rica in 1975 \[[@B2], [@B6]\]. In 1988, an outbreak in Somalia, Africa, was reported reaching 11,000 people \[[@B7]\]. In Latin America, the first detection of HEV was described in Mexico, during an outbreak between 1986 and 1987, with detection of genotype 2 \[[@B5], [@B8]\]. The largest epidemic described was in China between 1986 and 1988, presenting 120,000 people with the disease caused by genotype 1 \[[@B9]\].

HEV genome was first cloned in the early 1990s, and genotypes 3 and 4 were identified in 1995 and 2003, respectively \[[@B4], [@B6], [@B7]\]. Other genotypes, such as 5, 6, and 7, have already been documented in animals, and these are considered reservoirs of the virus \[[@B10], [@B11]\].

2. Hepatitis E Virus, Transmission, and Diagnosis {#sec2}
=================================================

Hepatitis E virus (HEV) is a small, nonenveloped virus (27--34 nm) with icosahedral symmetry in the Hepeviridae Family. HEV is divided into two genera:*Orthohepevirus* with four species (A--D) and*Piscihepevirus* with one species (A) \[[@B6], [@B10], [@B12], [@B13]\].*Orthohepevirus A*species include almost all mammalian HEV variants; it is divided into seven genotypes, of which at least five of them are of interest in human public health. First, genotypes 1 and 2 (HEV-1 and HEV-2) infect only humans and are responsible for sporadic cases and large waterborne outbreaks in endemic areas. Furthermore, genotypes 3 and 4 (HEV-3 and HEV-4) are able to infect humans and animals and are enzootic in pigs, which are considered the main reservoir of HEV in the environment \[[@B4], [@B6], [@B10]\]. Until now, only one report of human HEV infection with genotype 7 (HEV-7) has been documented \[[@B14]\].

*Orthohepevirus B* species include viruses, which infect birds, while*Orthohepevirus C* include viruses that infect rat and ferret. Viruses isolates were detected in bats, and they were grouped into*Orthohepevirus D*species.*Piscihepevirus* genus is formed by only one species,*Piscihepevirus A*, and comprises all the isolates identified in trout fish \[[@B15]\].

Nevertheless, there is one serotype of hepatitis E circulating worldwide \[[@B4], [@B6], [@B10], [@B16], [@B17]\]. To our knowledge, [Table 1](#tab1){ref-type="table"} shows the genotypes detected in humans and animals, as well as geographic distribution in which the genome was recently detected and frequently circulating.

HEV contains a 7.2 kb single-stranded, positive-sense RNA genome that consists of three overlapping open reading frames (ORF) with distinct functions: ORF1, ORF2, and ORF3. ORF1 encodes a nonstructural polyprotein (with 1690 amino acids (aa)), which consists of proteins required for RNA replication such as methyltransferase, papain-like cysteine protease, RNA helicase, and RNA-dependent RNA polymerase. ORF2 is the most important structural protein for targeting HEV vaccine development since it encodes the capsid protein, which carries neutralizing epitopes inducing antibody production in the host and reservoirs. ORF3 has 123 aa, overlaps with ORF2, and encodes a small multifunctional protein involved in viral particle secretion \[[@B4], [@B6], [@B10], [@B17]\].

Complete particles of HEV are vulnerable to boiling or frying and they become inactivated after 5 minutes at temperatures above 90°C. To completely inactivate HEV in the food, an internal temperature of 71°C for 20 min is necessary \[[@B18]\]. HEV is also susceptible to chlorine disinfection in fomites and water supplies \[[@B4], [@B6], [@B19]\].

Hepatitis E is mainly transmitted by a fecal-oral route through contaminated water ingestion and the consumption of undercooked pork or wild boar ([Table 1](#tab1){ref-type="table"}). However, transmission by blood components is increasingly recognized \[[@B20], [@B21]\]. Poor hygiene and untreated sewage are correlated with infections by the HEV-1 and HEV-2 genotypes in developing countries. Outbreaks and sporadic cases are related to the transiently contamination of water supplies. Instances of autochthonous hepatitis E by genotypes 3 and 4 are increasing in developed countries with high consumption of raw or uncooked pork meat since hepatitis E is categorized as a zoonotic disease with domestic animals as reservoir (mainly pigs) ([Table 1](#tab1){ref-type="table"}) \[[@B4], [@B6], [@B10], [@B17]\].

The diagnosis of HEV infection is not easy considering the short period of HEV viremia, which is not always concomitant with the onset of symptoms. Serum samples are used to perform molecular detection of RNA and specific-antibodies against capsid (ORF2) as the main tool for HEV diagnosis. Two serological markers can be used to investigate the presence of past or recent HEV infection. The first is anti-HEV IgM, which indicates the acute phase, and the second is anti-HEV IgG, which indicates current infection when observed together with anti-HEV IgM detection or past contact when it is detected alone \[[@B13], [@B16], [@B22], [@B23]\]. RNA testing is usually useful when serology is difficult to interpret due to cross-reactivity with polyclonal antibody immune response and in immunocompromised patients, in which the antibody response may be undetectable. Nevertheless, the technique is vital for genotyping for epidemiological purposes \[[@B24]\].

3. Epidemiology {#sec3}
===============

According to the World Health Organization (WHO), HEV infection is one of the most common causes of acute hepatitis and has a large distribution worldwide \[[@B25]\]. It is estimated that 2.3 billion people have already been infected with HEV, and 70,000 deaths are attributed to HEV annually \[[@B26], [@B27]\]. Two distinct epidemiological patterns have been observed in different regions of the globe. These patterns seem to be correlated with the distribution of HEV genotypes, transmission routes, source of virus infection, disease prevalence, and, in some cases, clinical characteristics of the disease. The epidemiology and clinical features of HEV infection are primarily determined by the predominant genotype in the region and their respective hosts ([Table 1](#tab1){ref-type="table"}). Characteristics of these two faces of hepatitis E infection correlated with geographic distribution are summarized in [Figure 1](#fig1){ref-type="fig"} according to Center of Diseases Control and World Health Organization \[[@B28], [@B29]\].

HEV genotypes 1 and 2 are highly endemic in tropical and subtropical areas where hepatitis E occurs as outbreaks and sporadic cases transmitted by a fecal-oral route through contaminated water caused by genotypes 1 or 2 \[[@B30]\]. Outbreaks and sporadic cases can occur globally, but there are distinct circulations of HEV genotypes, as in Asia and Africa, where genotypes 1 and 2 are predominant, respectively ([Table 1](#tab1){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}). Additionally, genotypes 3 and 4 are also frequently detected in Asia \[[@B29], [@B31]--[@B33]\] ([Table 1](#tab1){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}). The prevalence of antibodies against HEV (anti-HEV IgG) in those regions is between 3 and 27% \[[@B29], [@B34]\].

Outbreaks of HEV-1 and HEV-2 have been documented in areas with limited access to water and inadequate sanitary conditions, generally in resource-limited countries \[[@B25]\] ([Figure 1](#fig1){ref-type="fig"}). The WHO showed that African and Asia are the areas most affected by infection of these genotypes. The prevalence of anti-HEV IgG in Africa ranges from 4.6 to 10.7% in the general population \[[@B29], [@B35]\]. Asia shows a higher prevalence than Africa with anti-HEV IgG frequencies that can reach 34.8% to 94% \[[@B29], [@B34], [@B36]--[@B38]\].

Outbreaks of HEV-1 and 2 reach thousands of people, and up to 15% of the infected population present signals and symptoms \[[@B39], [@B40]\]. Overall morbidity rates are higher among teenagers and young adults (between 10 and 40 years old) but lower in children and elderly people \[[@B41]\]. High morbidity and severity have been observed among pregnant women and patients with preexisting chronic liver disease, leading to fulminant hepatitis \[[@B42], [@B43]\]. The clinical disease is characterized by acute, self-limited hepatitis that is clinically and biochemically indistinguishable from other types of viral hepatitis \[[@B44]\] ([Figure 1](#fig1){ref-type="fig"}).

Besides fecal-oral transmission, vertical \[[@B45], [@B46]\] and parenteral \[[@B47]\] routes of HEV-1 and 2 transmission are also recognized. HEV infection with genotypes 1 frequently determines symptomatic disease in pregnant women that can be severe, especially in the third trimester determining acute liver failure (ALF) with a mortality rate of 15--25% \[[@B48], [@B49]\]. Infection with HEV-1 during pregnancy is also related to an increased risk of adverse outcomes of pregnancy as spontaneous abortion, fetal death in utero, and premature delivery in patients with icteric hepatitis or with ALF caused by HEV \[[@B50], [@B51]\]. In addition, vertical transmission can result in complications to the fetuses and neonates, such as anicteric or icteric hepatitis hypoglycemia and neonatal death \[[@B49], [@B50]\]. High mortality in pregnant women is mostly observed in outbreaks of hepatitis E in India, and findings showed that elevated viral load as well as hormones levels alterations, immunological changes, and poor nutrition during pregnancy have been correlated with worst outcome, which makes women more susceptible \[[@B49]--[@B53]\].

Regions with adequate sanitary conditions and well-controlled water supplies are considered low endemic areas for hepatitis E, such as Europe, East Asia (including China), and the Americas ([Figure 1](#fig1){ref-type="fig"}). In these regions, the disease is less frequent and occurs as sporadic cases \[[@B13], [@B29], [@B54], [@B55]\], in which anti-HEV prevalence is 7% to 10% \[[@B29], [@B54], [@B55]\]. Autochthonous cases of HEV infection in these areas appear to be associated with occasional zoonotic transmission by genotypes 3 and 4 from domestic animals (most often from pigs to humans). This transmission can occur through the ingestion of raw or undercooked food containing the virus, especially swine products \[[@B56]\].

Additionally HEV (especially genotype 3 in Europe) can be iatrogenically transmitted between humans through infected blood and blood products \[[@B57]\]. Transfusion-associated HEV infections have been reported also in Japan (for genotypes 3 and 4) and China (for genotypes 1 and 4), although this pathway is less common than the zoonotic and the waterborne infections \[[@B58], [@B59]\].

The prevalence rates of anti-HEV in Europe could be explained by pork consumption, as in France and Germany, where the seroprevalence is 17% and 35%, respectively. In France, anti-HEV IgG prevalence was also high in an investigation of blood banks (52%), which reinforces the findings about the prevalence of hepatitis E in Europe. Recent studies detected genotypes 1, 3, and 4 in Europe \[[@B29], [@B60]--[@B63]\]. In low endemic areas, HEV-1 is usually detected in travelers coming from endemic regions \[[@B29], [@B60]--[@B63]\].

In the Americas, the seroprevalence of anti-HEV IgG ranges from 3 to 31%, which can be explained by the sporadic HEV cases reported in the area \[[@B29], [@B64], [@B65]\]. Genotypes 1 through 3 have been documented in humans and animals in Uruguay (HEV-1 and HEV-3), Colombia (HEV-3), Argentina (HEV-3), Mexico (HEV-2, only humans), Venezuela (HEV-1 and HEV-3), Brazil (HEV-3), and the United States of America (HEV-3) \[[@B5], [@B8], [@B10], [@B29], [@B64]--[@B70]\].

Conventionally, symptomatic HEV-3 and HEV-4 infection results in self-limited acute hepatitis in humans. However, in recent years, the occurrence of chronic hepatitis by infection, especially with genotype 3, has been described in immunosuppressed patients, especially posttransplant patients \[[@B71]--[@B73]\]. The transfusion of blood and blood products, solid organ transplantation (SOT), stem cells, and pork-derived products constitute the principal sources of infection, especially for immunosuppressed individuals. However, they can be avoided by screening biological samples in blood banks \[[@B74], [@B75]\]. Besides, patients with preexisting chronic liver disease and those infected with HEV-3 can progress to fulminant hepatitis, as observed with genotype 1 \[[@B76]\].

Acute or chronic HEV infection caused by genotypes 1--4 may also cause extrahepatic manifestations that include neurological disorders, kidney injury, acute pancreatitis, and hematological abnormalities. Particularly for HEV infection, physicians need to have attention to neurological manifestations such as Guillain-Barré syndrome, brachial neuritis, and meningoencephalitis, which are a risk, despite rare occurrence in viral hepatitis \[[@B77]\].

4. Hepatitis E Vaccination {#sec4}
==========================

The need for hepatitis E vaccine is related to its worldwide distribution. The WHO estimates that 44,000 deaths were caused by HEV in 2015, representing 3.3% of the mortality due to viral hepatitis \[[@B29]\]. Normally, pregnant women with HEV-1 infection have the worst outcome and have been considered the main target group to receive vaccinations \[[@B35], [@B52], [@B78], [@B79]\]. Public health surveillance in pregnant and nonpregnant population is also extremely important for controlling the number of outbreaks, along with improving sanitation in endemic and nonendemic countries \[[@B13], [@B31], [@B34], [@B54], [@B60], [@B62], [@B63], [@B80], [@B81]\].

It is not feasible to develop live attenuated or inactivated vaccines for hepatitis E virus by*in vitro* cell culture replication \[[@B82]--[@B85]\]. Passive immunoprophylaxis has not succeeded in preventing infection, but only the symptoms of hepatitis. On the other hand, active immunization has been demonstrated to be effective in experimental animal models \[[@B86]\]. Thus, several studies have focused on the development of recombinant vaccines \[[@B82]--[@B85]\].

The only vaccine that is commercially available is the HEV 239 vaccine (Hecolin, Xiamen Innovax Biotech, China), which has been registered in China since 2011. However, it has not yet been approved in other countries \[[@B87], [@B88]\]. This recombinant vaccine which contains 26 aa and is an extension from the N terminal of another peptide, E2, from the HEV capsid protein, which is the one major structural protein. This approach for the vaccine is possible because HEV is antigenically conserved, presenting only one identified serotype, which was observed to be protective for all four HEV genotypes (HEV-1, HEV-2, HEV-3, and HEV-4) \[[@B87], [@B89]--[@B91]\].

The HEV 239 vaccine is protective against hepatitis in animal models based on Rhesus monkeys immunized and challenged with infectious virus strains (genotypes 1 and 4) \[[@B83], [@B85]\]. The vaccine was found to induce effective neutralizing antibodies against HEV \[[@B83], [@B92], [@B93]\]. In mouse models, a strong T cell-dependent antibody response was observed after vaccination, which was partly attributed to two T cell epitopes located in the portion of aa 533--552 on the HEV capsid peptide \[[@B6], [@B82], [@B94]\].

The vaccination schedule in China with HEV 239 vaccine involves three doses administered intramuscularly at months 0, 1, and 6. In 2010, Zhu and colleagues performed a phase 3 trial in healthy adults (\>16 years old) in China using the HEV 239 vaccine, which contained 30 *μ*g of the purified antigen plus aluminum hydroxide as adjuvant. The vaccine\'s efficacy is greater than 90% for 1 year after one dose and for 4.5 years after three doses \[[@B94]--[@B96]\]. Additionally, the HEV 239 vaccine is safe for both pregnant women and the fetus \[[@B90]\].

Considering that only China has experience with vaccination against hepatitis E, and HEV infection has remained a health problem, the cost-effectiveness of the HEV vaccine has been debated. The Hecolin HEV 239 vaccine from Xiamen Innovax Biotech costs around USD 17.60--41.70 per dose \[[@B78], [@B88]\], which is less expensive than hepatitis A vaccine (median price: USD 23.21 per dose) \[[@B97]\]. Consequently, as immunization can reduce the cost of hospitalization and treatment, the implementation of hepatitis E vaccine could be a cost-effective health intervention at the market vaccine price. In addition, given the budget limitations in developing countries, the single-dose schedule would be more realistic to apply and could influence the adaption of immunization policies in highly endemic and low endemic countries.

Nevertheless, further studies are necessary to establish or improve HEV immunization worldwide in humans and animals (e.g., domestic pigs). Furthermore, health surveillance will be very important for monitoring the prevalence and incidence of HEV before and after immunization. In addition to these efforts, developing countries still need sanitary and environmental improvements. For more clarification, [Table 2](#tab2){ref-type="table"} briefly summarizes the ways of preventing hepatitis E nowadays.

5. Treatment {#sec5}
============

Treatment for hepatitis E infection can be justified by the chronic and persistent infections commonly caused by genotype 3 and involved with immunosuppressive or immunocompromised conditions \[[@B32], [@B98]--[@B101]\]. SOT, HIV, and hemodialysis patients are populations that are at risk for chronic hepatitis E \[[@B32], [@B98]\]. Several studies describe that HEV clearance was achieved by administering decreasing doses of immunosuppressants that target T-cells after SOT \[[@B98], [@B102], [@B103]\]. Therapies using ribavirin and pegylated-interferon succeeded in establishing a sustained virologic response after 3--6 months of treatment after SOT, with patients presenting a restoration of lymphocyte count \[[@B98]\].

Recently, a large follow-up study related the effect of ribavirin as a monotherapy for SOT recipients with prolonged HEV viremia. Kamar and colleagues observed HEV clearance in 95% of patients on ribavirin monotherapy with a median dose of 600 mg/day for 3--6 months. The only side effect in this study was anemia, which required reduction of the ribavirin dose in 29% of the patients, as well as the use of erythropoietin (54%) and blood transfusion (12%) \[[@B32], [@B98]\]. Pegylated-interferon had a successful effect on liver-transplant patients with immunosuppression and hemodialysis who presented HEV viremia. However, it is not indicated in other types of SOT, such heart, lung, and kidney SOT, since it can increase the risk of organ rejection \[[@B98], [@B100]\]. Thus, the recent findings suggest that ribavirin is an antiviral therapy to treat HEV chronic infection in immunocompromised patients. [Figure 2](#fig2){ref-type="fig"} shows the therapies normally used to treat hepatitis E infection according to patient\'s clinical situation in recent studies.

HEV replication is inhibited by the inactivation RNA polymerase function using antiviral drugs such as zinc salt and nucleoside analogue 2′-C-methylcytidine (2CMC) in human cell lines*in vitro*. Thus, they have been suggested as potential drugs to control HEV infection \[[@B17], [@B103]\]. When 2CMC is administered with ribavirin, the activity and efficacy of ribavirin are compromised \[[@B103]\]. Other drugs have also been tested*in vitro*, such as sofosbuvir, calcineurin inhibitors, and mTOR inhibitors, which may help in virus clearance and show promise for future treatments \[[@B6], [@B17], [@B103]\].

There is few information about treatments against acute hepatitis E infection, for which ribavirin is recommended to treat immunocompetent and immunocompromised individuals \[[@B6], [@B99], [@B102]\]. Nevertheless, safe and effective treatment has been achieved with 3-4 weeks of ribavirin treatment, showing the reestablishment of liver enzymes levels in immunocompetent patients who usually need symptomatic treatment due to the short duration of HEV viremia, as well as immunocompromised subjects who are characterized by elevated transaminase levels with HEV viremia in the acute phase \[[@B6], [@B102]\].

6. Conclusion {#sec6}
=============

Several studies have been performed to investigate HEV infection and reduce the numbers of hepatitis cases caused by this etiology. Considerable improvements in vaccination and treatment have been achieved, but there have been limitations that bound the success of HEV elimination. This is particularly true in developing countries, where HEV remains an important health problem. In this review, we have presented an update on the cost-effectiveness vaccination to spread the program worldwide. Together with information about treatment of immunocompromised and immunocompetent individuals, approaches were suggested to help continue the surveillance and optimize future research in this area.
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###### 

HEV genotypes in human and animals hosts and their geographical distribution.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Genotypes   Host species                                        Geographical distribution                       References
  ----------- --------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------
  1           Human                                               Asia, Africa, Central America                   Nelson et al., 2016 \[[@B104]\]; Kamar et al., 2014 \[[@B32]\];\
                                                                                                                  Kamar et al., 2012 \[[@B105]\]

  2           Human                                               West Africa, Mexico                             Nelson et al., 2016 \[[@B104]\]; Kamar et al., 2014 \[[@B32]\];\
                                                                                                                  Kamar et al., 2012 \[[@B105]\]

  3           Human, pig, wild boar, red deer, mongoose, rabbit   Europe, East Asia, South Africa, and Americas   Pinto et al., 2017 \[[@B5]\]\
                                                                                                                  Nelson et al., 2016 \[[@B104]\]; Kamar et al., 2014 \[[@B32]\];\
                                                                                                                  Kamar et al., 2012 \[[@B105]\];

  4           Human, pig, sheep, cattle                           Asia, and Europe                                Pinto et al., 2017 \[[@B5]\]\
                                                                                                                  Nelson et al., 2016 \[[@B104]\]; Kamar et al., 2014 \[[@B32]\];\
                                                                                                                  Kamar et al., 2012 \[[@B105]\]; Wang and Ma, 2010 \[[@B106]\];

  5           Wild boar                                           Asia                                            Pinto et al., 2017 \[[@B5]\]\
                                                                                                                  Sridhar et al., 2017 \[[@B107]\];\
                                                                                                                  Smith et al., 2015 \[[@B15]\];\
                                                                                                                  Kamar et al., 2014 \[[@B32]\]

  6           Wild boar                                           Asia                                            Pinto et al., 2017 \[[@B5]\]\
                                                                                                                  Sridhar et al., 2017 \[[@B107]\];\
                                                                                                                  Smith et al., 2015 \[[@B15]\];\
                                                                                                                  Kamar et al., 2014 \[[@B32]\]

  7           Dromedary camel                                     Asia                                            Woo et al., 2014 \[[@B11]\]\
                                                                                                                  Sridhar et al., 2017 \[[@B107]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Preventive measures for hepatitis E in 2010 \[[@B4], [@B18], [@B19], [@B29], [@B104], [@B108]\].

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Preventive action                       Procedures
  --------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Virus inactivation                      Water and food to ingest: boiling or frying at temperatures above 90°C, wash fruit and vegetables with chlorine solutions;\
                                          fomites and water supplies: chlorine disinfection.

  Sanitation, hygiene, and surveillance   Community: treat sewage and water supplies.\
                                          Personal: wash hands; use gloves to prepare food.\
                                          Healthcare workers: wear individual biosafety clothes during outbreaks, and in blood procedure manipulation; perform laboratorial screening in the blood bank.

  Vaccination                             Perform mass vaccination with a safety vaccine to susceptible people and animals.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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